Compounded GLP-1s After June 29: What's Changing and What to Do Next
Last updated: 2026-06-29
If you've been getting compounded semaglutide or tirzepatide from a 503B outsourcing facility — the larger, FDA-registered compounding pharmacies that supply most telehealth weight-loss programs — your access is changing today. The FDA's extended comment period for 503B compounders closes, and enforcement of the prohibition on copying name-brand GLP-1s moves to the next phase.
Here's what that actually means for you, what happens with Medicare starting July 1, and the realistic paths forward for anyone who wants to stay on a GLP-1 or find a credible alternative.
What Compounded GLP-1s Were — and Why Millions Switched to Them
Ozempic (semaglutide for diabetes), Wegovy (semaglutide for weight loss), Mounjaro (tirzepatide for diabetes), and Zepbound (tirzepatide for weight loss) became household names fast. They also became impossible to get at a price most people could afford. Branded Wegovy runs $1,300–$1,700 per month without insurance. Zepbound is similar.
When both drugs landed on the FDA's drug shortage list — semaglutide in 2022, tirzepatide in 2022 as well — federal law opened a window. Compounding pharmacies, which specialize in making customized medications, were legally allowed to produce copies of drugs on the shortage list. Both 503A pharmacies (small, patient-specific operations licensed by state pharmacy boards) and 503B outsourcing facilities (larger manufacturers registered with the FDA) jumped into the market.
The result: millions of Americans accessed semaglutide or tirzepatide injections for $150–$350 per month through telehealth platforms. Companies like Hims & Hers, Ro, Henry Meds, and dozens of others built their weight-loss practices almost entirely on compounded GLP-1s.
How the FDA Shut It Down — In Stages
The FDA declared the semaglutide shortage over in February 2025 and the tirzepatide shortage over in May 2025. Under federal law, once a drug is off the shortage list, compounding pharmacies can no longer make copies — the shortage exemption disappears.
The FDA enforced this in two phases:
503A pharmacies (the smaller, patient-specific compounders) faced an earlier deadline — roughly 60–90 days after the shortage ended for each drug. By spring 2025, most 503A semaglutide compounding was already prohibited. 503A tirzepatide followed shortly after.
503B outsourcing facilities — which supplied most of the high-volume telehealth programs — were given more time, partly because they're FDA-registered and held to higher manufacturing standards, and partly because the scale of disruption was enormous. Millions of patients were receiving these medications. The FDA opened a comment period and extended the enforcement window multiple times through 2025 and into 2026.
That comment period closes today, June 29. The enforcement posture that follows is the final one.
What "Enforcement" Actually Means After June 29
The FDA doesn't raid pharmacies on the day a deadline passes. Enforcement ramps. But the legal exposure for 503B facilities shipping compounded semaglutide or tirzepatide without an active shortage exemption is now clear — and most of the large compounders have already wound down or are winding down these product lines.
What you'll likely see in the next 30–90 days:
- Telehealth platforms that relied on 503B-compounded GLP-1s will pause or cancel subscriptions, often with short notice
- Some platforms will pivot to prescribing brand-name drugs and helping patients pursue insurance coverage
- 503B pharmacies that ignored the deadline will face warning letters, import alerts, and potential injunctions — not fines that they can absorb quietly
- A secondary market of overseas pharmacies and gray-market suppliers will grow; these are unregulated and carry real safety risks
If you're currently mid-subscription and haven't heard from your provider, reach out now. Don't wait for an automated email telling you your next shipment won't arrive. For a plain breakdown of the enforcement timeline itself, see What Happens After June 29? The FDA Semaglutide Deadline Explained.
The Medicare Angle: What Changes July 1
Starting July 1, the Medicare Part D landscape for anti-obesity medications shifts again — and it matters for anyone on or considering a GLP-1.
Medicare's coverage of GLP-1s has been the most consequential insurance policy debate in weight medicine. Here's where things stand:
What Medicare has covered (and still covers): GLP-1 receptor agonists prescribed for Type 2 diabetes — Ozempic, Mounjaro, Trulicity — have been covered under Part D when the indication is diabetes management. If you have a diabetes diagnosis and your doctor prescribes semaglutide for glycemic control, Medicare covers it.
What Medicare still doesn't cover: Wegovy and Zepbound, the versions of these drugs FDA-approved specifically for obesity, have historically been excluded under Medicare rules that bar coverage of "drugs used for weight loss." The Inflation Reduction Act drug-pricing provisions that took effect in 2026 affected pricing negotiations — but the obesity-drug exclusion has been a legislative fix that Congress has debated through the Treat and Reduce Obesity Act (TROA) without final passage as of this writing.
What to watch for July 1 and beyond: If your plan year renews July 1, check your formulary. Some Medicare Advantage plans have voluntarily added coverage for anti-obesity medications ahead of any federal mandate. That coverage can change plan-to-plan and year-to-year.
If you're in Medicare and paying out of pocket for compounded GLP-1s, this regulatory moment is also a moment to revisit your coverage options. Work with a licensed Medicare insurance agent — not a telehealth platform — to understand what your specific plan covers. For the full state of play, see Does Medicare Cover Ozempic and Wegovy in 2026? What to Know Before July 1.
Your Real Options Right Now
This is the practical part. If your compounded GLP-1 access is going away, you have four realistic paths:
Option 1: Pursue Brand-Name GLP-1s Through Insurance
The most durable solution. Yes, this requires prior authorization, documentation of BMI and weight-related comorbidities, sometimes a history of supervised diet attempts. But people who go through this process and get approved pay $0–$50/month instead of $1,300.
Start with your primary care doctor, not a telehealth platform. A PCP who knows your history can build a more persuasive case to your insurer than a telehealth prescriber who's seen you once via video.
If your insurer denies coverage, file an appeal. First-level appeals for GLP-1 denial are overturned at meaningful rates when the clinical documentation is thorough.
Option 2: Manufacturer Savings Programs
Novo Nordisk (maker of Wegovy) and Eli Lilly (maker of Zepbound) both offer savings programs for commercially insured patients. These are not charity programs — they require commercial insurance that covers the drug. But if your insurance covers it even partially, these programs can cap your out-of-pocket cost significantly.
Novo Nordisk's NovoCare program and Lilly's Savings Card programs change terms periodically, so verify current eligibility directly on their websites.
Option 3: Telehealth Platforms Pivoting to Brand-Name Access
Some telehealth companies that built on compounded GLP-1s are now pivoting to helping patients navigate brand-name access — prior auth assistance, insurer appeals, and cash-pay pricing for brand-name drugs in some cases. Sequence by Found and Noom Med are two platforms that have invested in this kind of insurance navigation support.
Affiliate Disclosure: This article may contain affiliate links. If you make a purchase through these links, we may earn a small commission at no extra cost to you. We only recommend products we genuinely believe in. This helps support our work and allows us to continue providing free content.
The cash-pay price for brand-name drugs is still high, but some platforms have negotiated direct pricing or offer payment plans that make it more manageable than retail pharmacy pricing.
Option 4: High-Protein, Low-Insulin Diet as a Bridge or Alternative
This is the path that doesn't require a prescription, an insurance fight, or $1,000 a month — and it's more effective than most people realize when executed seriously.
GLP-1 medications work primarily by slowing gastric emptying, reducing appetite, and improving insulin sensitivity. A high-protein, lower-carbohydrate diet hits the same metabolic levers through food.
The evidence is real: a diet centered on 1.2–1.6g of protein per kilogram of body weight, with carbohydrates kept below 100g/day and seed oils replaced with stable saturated and monounsaturated fats, produces meaningful appetite suppression in most people within 2–3 weeks. It's not as dramatic as a GLP-1 injection, but it's not nothing — and for people who can't access or afford medication, it's the lever they actually have. If you're coming off a GLP-1 rather than never starting one, our After Ozempic seed oil free eating plan covers how to prevent rebound weight gain specifically.
We've covered the mechanics of this in detail in our seed oil elimination guide and our 7-day omega-3 meal plan. If you've been relying on compounded GLP-1s as your primary weight-loss strategy, now is a good time to build the dietary foundation that works with or without medication.
What to Watch for in Gray-Market Alternatives
When a popular, affordable treatment gets restricted, a gray market fills the gap. You will see:
- Overseas pharmacies (often based in India or Turkey) advertising "pharmaceutical-grade" semaglutide with no prescription required
- Peptide research vendors selling "research chemicals" — semaglutide and tirzepatide labeled "not for human use" — with obvious wink-and-nod marketing
- Telehealth platforms based outside the US that claim FDA compliance without actual oversight
These carry serious risks. Dosing errors with GLP-1s cause significant nausea, vomiting, and in severe cases dangerous complications. Without pharmaceutical-grade manufacturing controls, contamination is a real issue. And you have no legal recourse when something goes wrong.
If you can't access or afford brand-name drugs and diet strategies aren't sufficient, talk to your doctor — not the internet — about your options. That conversation is worth having.
The Berberine Question
You'll see "nature's Ozempic" claims for berberine flooding social media as GLP-1 access tightens. Here's the honest answer: berberine has demonstrated modest blood sugar and insulin-sensitivity benefits in studies, primarily in people with metabolic syndrome or Type 2 diabetes. The mechanism partially overlaps with GLP-1 activity, hence the comparison.
What berberine does not do: produce the appetite suppression and sustained weight loss seen in GLP-1 clinical trials. The "1000mg twice daily" regimen that circulates online has real GI side effects and drug interactions (it inhibits cytochrome P450 enzymes, which matters if you take statins, blood thinners, or several other common medications).
Berberine may be a reasonable supplement in a broader metabolic health protocol. It is not a substitute for a GLP-1, and marketing it as one is misleading. Talk to your doctor before adding it, especially if you're on other medications.
The Takeaway
The compounded GLP-1 window is closing. That's not a surprise — it was always a temporary exemption tied to drug shortages. The question is what you do with the time you have now.
If you're currently on compounded semaglutide or tirzepatide: contact your provider today to understand your timeline. Don't wait for your subscription to lapse without a plan.
If you've been thinking about starting: the compounded route is essentially closed. Pursue brand-name coverage through your insurance, or evaluate whether your dietary and lifestyle changes can carry the weight without medication — literally.
And if you're in Medicare: July 1 is a good date to call your plan and ask exactly what GLP-1 coverage you have, if any. The landscape is changing faster than the plan documents.
Stay Current on Weight Loss Policy
FDA policy on compounding, Medicare coverage expansions, and new drug approvals are all moving fast in 2026. We track what actually matters for people trying to lose weight without spending a fortune.
Join our newsletter and we'll send you a weekly summary of what's changing — no filler, no affiliate spam, just the updates worth knowing.
GLP-1 Policy Is Moving Fast. We'll Keep You Posted.
Join our newsletter for the latest updates.